- Home
- QNTM vs SEPN Comparison
QNTM vs SEPN Comparison
Compare QNTM & SEPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QNTM
- SEPN
- Stock Information
- Founded
- QNTM 1998
- SEPN 2022
- Country
- QNTM Canada
- SEPN United States
- Employees
- QNTM N/A
- SEPN N/A
- Industry
- QNTM
- SEPN
- Sector
- QNTM
- SEPN
- Exchange
- QNTM NYSE
- SEPN NYSE
- Market Cap
- QNTM 9.1M
- SEPN 1.0B
- IPO Year
- QNTM N/A
- SEPN 2024
- Fundamental
- Price
- QNTM $4.08
- SEPN $21.35
- Analyst Decision
- QNTM
- SEPN Strong Buy
- Analyst Count
- QNTM 0
- SEPN 4
- Target Price
- QNTM N/A
- SEPN $43.67
- AVG Volume (30 Days)
- QNTM 220.7K
- SEPN 482.6K
- Earning Date
- QNTM 01-14-2025
- SEPN 02-15-2025
- Dividend Yield
- QNTM N/A
- SEPN N/A
- EPS Growth
- QNTM N/A
- SEPN N/A
- EPS
- QNTM N/A
- SEPN N/A
- Revenue
- QNTM N/A
- SEPN $981,000.00
- Revenue This Year
- QNTM N/A
- SEPN $406.62
- Revenue Next Year
- QNTM N/A
- SEPN N/A
- P/E Ratio
- QNTM N/A
- SEPN N/A
- Revenue Growth
- QNTM N/A
- SEPN N/A
- 52 Week Low
- QNTM $2.70
- SEPN $18.62
- 52 Week High
- QNTM $70.85
- SEPN $28.99
- Technical
- Relative Strength Index (RSI)
- QNTM 49.93
- SEPN N/A
- Support Level
- QNTM $3.50
- SEPN N/A
- Resistance Level
- QNTM $4.67
- SEPN N/A
- Average True Range (ATR)
- QNTM 0.69
- SEPN 0.00
- MACD
- QNTM 0.07
- SEPN 0.00
- Stochastic Oscillator
- QNTM 46.00
- SEPN 0.00
About QNTM QUANTUM BIOPHARMA LTD
Quantum BioPharma Ltd formerly FSD Pharma Inc is a biopharmaceutical company developing three clinical candidates with the potential to address neuropsychiatric, neurodegenerative, and inflammatory disorders. Along with its subsidiaries, the group is focused on pharmaceutical research and development of its compound, FSD201, an ultra-micronized PEA, for the treatment of inflammatory diseases; Lucid-Psych is used in the treatment of mental health disorders and Lucid-MS is used in the treatment of neurodegenerative disorders. The company operates in two segments: Biopharmaceutical and Strategic Investments.
About SEPN SEPTERNA INC
Septerna Inc is a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by a proprietary Native Complex Platform. Its industrial-scale platform aims to unlock the full potential of GPCR therapies. The group discovery and development of a pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic disease. Its pipeline includes SEP-786 (PTH1R), SEP-631 (MRGPRX2), TSHR, and GLP-1R, GIPR, GCGR.